Aakaar Medical Technologies Limited · NSE:AAKAAR
Aakaar Medical Technologies — H1 FY27 Earnings Presentation
39 slides from Aakaar Medical Technologies's earnings presentation, Oct 30, 2026
Slide 1: Cover letter to NSE: press release and investor presentation
Aakaar Medical Technologies Limited (formerly: Aakaar Medical Technologies Pvt.Ltd.) A-801, Heritage Plaza, Teli Gali Cross Road Andheri (East), Mumbai – 400 069 INDIA Mob: + 91 9820317468 E-mail: [email protected] CIN No.: L74900MH2013PLC244717 www.aakaarmedical.in GST No: 27AALCA7587Q1ZK Octob
Slide 2: Aakaar Medical Technologies Investor Presentation H1 FY27
INDIA'S 1ST MEDICAL AESTHETIC NSE LISTED COMPANY Aakaar Medical Technologies Limited Investing in & Building the Future of Medical Aesthetics INVESTOR PRESENTATION – H1 FY 27 30th Oct 2026
Slide 3: Disclaimer
DISCLAIMER This presentation contains certain “forward looking statements” that are based on current expectations, assumptions, estimates and projections about the business, financial performance, industry trends and markets in which we operate. Such statements include, but are not limited to, those
Slide 4: Company at a Glance
Company at a Glance (H1 FY27 vs H1 FY26) 13+ yrs industry INR 5.43 Cr INR 43.72 Cr EBITDA with the margin of 12.42% Revenue from ops up 72.6% YoY INR 1.06 Cr INR 3.54 Cr vs loss of INR 0.78 Cr Cash & Bank (Sep-26) Margin 8.10% 4500+ 129 100+ Doc & Clinics SKUs Sales Reps B2B2C Medical Aesthetics Pla
Slide 5: Resilience amidst all the odds – PAT positive for 10 years
Resilience amidst all the odds – PAT positive for 10 years | Strong revenue growth All values in INR Cr. PAT (INR Cr): positive every year, FY17–FY26 ~40% CAGR H1 PAT (INR Cr) 6.6 3.5 6.0 2.2 2.4 1.8 1.8 2.0 1.7 0.8 0.5 -0.8 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25 FY26 H1FY26 H1FY27 Demonetis-
Slide 6: Comprehensive Business Segments of Aesthetics Products, Devices & Device Consumables
Comprehensive Business Segments of Aesthetics Products, Devices & Device Consumables Key Business Segments (Professional In-clinic & At Home Use) A. Aesthetics Products B. Aesthetic Devices & Device Consumables Products for hair care, skin care & injectables which include oral supplements, Clinical
Slide 7: Recurring, High growth, Margin accretive and Asset light
Recurring, High growth, Margin accretive and Asset light Revenue Engine – Product-led; Outsourcing Capital Robust Distribution Network- Recurring Annuity based business Intensive activities Scalable and Penetrative • Recurring business through Aesthetic products (87%) • Partnered with leading CRDMOs
Slide 8: H1 Coverage: Serving Medical Professionals Nationwide
H1 Coverage: Serving Medical Professionals Nationwide 5000+ 100+ 1,000+ 40+ Dermats & Clinics MR executives Pharmacies Stockists The company's strategy of using doctor-dispensed products has successfully expanded its reach to a larger market, benefiting through : • Increase in trust through doctors'
Slide 9: Strategic Thrusts
Strategic Thrusts
Slide 10: Delivered as promised – Plan of Action during H1FY27
Delivered as promised – Plan of Action during H1FY27 41.64 43.72 10.93 7.42 219 206 188 25.32 5.43 160 3.54 H1 FY26 H2 FY26 H1 FY27 -0.78 H1 FY26 H2 FY26 H1 FY27 -0.23 Mar-25 Sep-25 Mar-26 Sep-26 H1 FY26 H2 FY26 H1 FY27 Revenue (INR Cr) EBITDA (INR Cr) PAT (INR Cr) Debtors (No. of Days) H2FY26 H2FY2
Slide 11: Robust Financial Performance YoY
Robust Financial Performance YoY Revenue (INR Cr) EBITDA (INR Cr) PAT (INR Cr) 43.72 5.43 3.54 25.3 -0.8 -0.23 H1FY26 H1FY27 H1FY26 H1FY27 H1FY26 H1FY27 67 11 7 62 10 6 FY25 FY26 FY25 FY26 FY25 FY26 Numbers rounded off Investor Presentation - 2026 10
Slide 12: Statement of Profit and Loss – H1FY27
Statement of Profit and Loss – H1FY27 All values in INR Cr. Particulars H1FY27 H1FY26 Revenue from operations 43.72 25.32 Other income 0.27 0.30 Total Income 43.99 25.62 COGS 21.25 11.44 Gross Profit 22.47 13.88 Margin 51.40% 54.78% Employee benefits expense 8.07 7.26 Other Expenses 8.97 6.85 EBITDA
Slide 13: Balance Sheet Items – H1FY27
Balance Sheet Items – H1FY27 All values in INR Cr. Particulars H1FY27 Particulars H1FY27 Equity and Liabilities Non-Current Assets Shareholders’ funds Property, Plant & Equipment (PPE) 0.24 a. Share capital 14.17 Intangible assets (incl. under development) 0.77 b. Reserves and surplus 43.92 Deferred
Slide 14: Historic Statement of Profit and Loss
Historic Statement of Profit and Loss All values in INR Cr. Particulars FY23 FY24 FY25 FY26 Revenue from operations 32.8 46.1 61.6 66.9 Other income 0.1 0.2 0.2 0.8 Total Income 32.9 46.3 61.8 67.7 COGS 15.0 20.9 26.2 28.20 Gross Profit 17.8 25.2 35.6 39.5 Margin 54.2% 54.6% 57.6% 59.34% Employee be
Slide 15: Historic Balance Sheet Items
Historic Balance Sheet Items All values in INR Cr. Particulars FY23 FY24 FY25 FY26 Particulars FY 23 FY 24 FY25 FY26 Equity and Liabilities Non-Current Assets Shareholders’ funds Property, Plant & Equipment (PPE) 0.4 0.3 0.2 0.1 a. Share capital 0.7 0.7 10.4 14.2 Intangible assets 0.01 0.01 0.01 0.5
Slide 16: The Big Picture: Five Launches. One Strategy.
The Big Picture: Five Launches. One Strategy. Dominant Aesthetics Ecosystem. LETYBO® SAYPHA® VM CORP. XOMAGE FOTOFINDER NEUROMODULATOR DERMAL FILLER REGENERATIVE SUITE PLANT EXOSOMES DIGITAL DERMOSCOPY US FDA-approved botulinum Austrian HA filler with 3-product Italian exosome Korean plant exosome P
Slide 17: Consistent Product Launch
Consistent Product Launch Devices DermLite DL5 Plus Consumables LAUNCH 2010 2011 2013 2014 2015 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 YEAR In-House Product Imported Products Investor Presentation - 2026 1
Slide 18: Focused on strengthening doctor skills
Focused on strengthening doctor skills The Program is Designed to Train and Certify Practicing Dermatologists & Students on theory & practical knowledge Dermal Fillers Threads Toxins MASTER CLASS IN Conducted under tutelage of highly experienced & qualified Doctors & Practitioners, MICA CONTOURING t
Slide 19: Creating market through consistent trainings & workshops
Creating market through consistent trainings & workshops YAAM ACAAD 8.0 • Conducted workshops to train Dermatologist & Cosmetic practitioners. • MICA, hands-on workshop is conducted across Tier-I & II cities to provide training to the practitioners. • Participated in 20+ International, National and
Slide 20: Aakaar's Flagship Conference
Aakaar’s Flagship Conference • Aakaar’s first flagship aesthetics conference — FAHA (Facial Aesthetics Harmony Approach), bringing together leading dermatologists, plastic surgeons and international faculty. • Strategic Significance: FAHA establishes Aakaar as not merely a provider of aesthetic prod
Slide 21: India's First Doctor-Owned, Doctor-Operated Medical Aesthetics Platform
XELIX India's First Doctor-Owned, Doctor-Operated Medical Aesthetics Platform India’s first organised, doctor-led aesthetics platform - built on clinical rigour, brand & product portfolio across various aesthetic doctor-led services, and a 12,000+ covered aesthetic doctor network. Why Xelix ? ♙ ₹ FO
Slide 22: Xelix – Current State & Journey Ahead
Xelix – Current State & Journey Ahead Current State 70+ Clinics FY28 Onwards – 3 FY26 FY27 24 years Cities 30 Clinics 100+ Clinics 500+ Clinics Model Validation Active Onboarding Functional Revenue Model Network effects drive organic Cross-sell across established Nationwide network of India’s top La
Slide 23: Why Xelix Wins
WHY XELIX WINS Six structural advantages that create a defensible, compounding business. Large, Underpenetrated TAM Unfair Advantage at Launch Asset-Light Compounding India’s medical aesthetics market is large, fast - Aakaar’s 12K+ doctor relationships and DODO model = zero capex per clinic. Each gr
Slide 24: Experienced and Passionate Leadership Team
Experienced and Passionate Leadership Team Mr. Dilip Meswani Dr. Rahul Sawakhande Mr. Rakesh Parekh Mr. Anoopkumar Pillai Founder & MD CEO & Executive Director Chief Financial Officer Company Secretary • B.Sc. from the University of • MBBS from Maharashtra • Associated with company • Fellow Member o
Slide 25: Supported by Strong Directors and Management Team
Supported by Strong Directors and Management Team Mr. Rajendra Dhandhukia Mr. Deepanjan Periwal Mr. Saurabh Chamoli Mr. Deepak Sharma Independent Director Independent Director National Sales Head National Sales Head • B.Sc. from the University of • Chartered Accountant and • National Sales Head – Te
Slide 26: Supported by Strong Directors and Management Team
Supported by Strong Directors and Management Team Mr. Abhash Meswani Ms. Shruti Mishra Ms. Milouni Meswani Vice President - Xelix Head Digital Marketing Head Marketing • MBA from Georgetown • MBA from Kellogg School of • BBA from Kingston University, University’s McDonough Management, Northwestern L
Slide 27: Annexure
Annexure
Slide 28: Aakaar is Uniquely Positioned in a Competitive Market
Aakaar is Uniquely Positioned in a Competitive Market Types of Offerings Types of Products and/or Devices Offered Products Devices Facial Aesthetics Body Contouring & Injectables Hair Removal Tattoo Removal DRHP filed Investor Presentation - 2026 27
Slide 29: Aakaar's Complete Range of Aesthetics Products
A. Aakaar’s Complete Range of Aesthetics Products Professional Skin Care Range 01 Addresses diverse skin concerns, combining science and innovation to deliver outstanding results. Includes peels, medi-facials, etc Professional Hair Care Range 02 Combines advanced formulations and innovative techniqu
Slide 30: Strong Segment Growth across Entire Spectrum of Aesthetics Solutions
Strong Segment Growth across Entire Spectrum of Aesthetics Solutions Revenue growth over last 3 years Injectable & Aesthetics Devices & Professional Homecare for Professional Contouring Device Consumables Skincare Skin & Hair Haircare 11 11 18 7 20 5 8 9 6 1 FY23 FY26 FY23 FY26 FY23 FY26 FY23 FY26 F
Slide 31: Aakaar Brand Sales Revenue
Aakaar Brand Sales Revenue: FY 2026 H1 FY 2027 Company’s 11 years of experience 22.4 Cr 14.9 Cr ensures their home-grown aesthetic products deliver premium quality and INR INR superior results Revenue from own brand products Revenue from own brand products Professional Skin Care Range Presence acros
Slide 32: Imported / Third Party Brands Sales Revenue
Imported / Third Party Brands Sales Revenue: Providing Indian consumers with FY 2026 H1 FY 2027 exclusive access to renowned global skincare and aesthetics brands INR 44.5 Cr INR 28.7 Cr Revenue from IMP brand products Revenue from IMP brand products Introducing innovative and high-quality internati
Slide 33: Strengthening Products Portfolio through In-licensing Tie-ups (FY 25-26)
Strengthening Products Portfolio through In-licensing Tie-ups with Reputable International Brands as on FY 25-26 Aakaar’s in-licensing agreements and collaborations with renowned international aesthetic brands allow them to distribute select high-demand products across India, currently contributing
Slide 34: Strengthening Products Portfolio through In-licensing Tie-ups (FY 26-27)
Strengthening Products Portfolio through In-licensing Tie-ups with Reputable International Brands FY 26-27 Aakaar’s in-licensing agreements and collaborations with renowned international aesthetic brands allow them to distribute select high-demand products across India, currently contributing to 70%
Slide 35: Range of Devices and Device Consumables for Innovative Aesthetics Solutions
Range of Devices and Device Consumables for Innovative Aesthetics Solutions Aakaar’s aesthetic devices utilize cutting-edge technology Brands Offered tailored to diverse skincare and haircare needs, with each device engineered for precision, safety and efficacy, ensuring superior results and minimal
Slide 36: Development Journey: From Concept to Commercial Release
From Concept to Commercial Release : Aakaar’s Product Development Journey Regulatory Compliance – Formulation and Trial – Prototype Development Feasibility Concept Development – Research & Ideation – 1 Month 2 Month – 2 Months Analysis – 1 Month 1 Month 1 Month • Ensure compliance with • Finalize pr
Slide 37: Ideation to Launch for Imported Products
Ideation to Launch for Imported Products Regulatory Compliance – Prototype Development – Feasibility Analysis – Identification – Research & Ideation – 10 Months 1 Month 1 Month 1 Month 1 Month • Hire a regulatory consultant • Import product Samples • Assess technical feasibility • Evaluate Idea • Ma
Slide 38: Key Clients
Key Clients Aakaar’s clients encompass a wide range of professionals and corporates, from individual doctors to renowned dermatology clinics, ensuring personalized and high-quality care. Some of Aakaar’s esteemed clients include : One of the largest chains of slimming, beauty, and fitness centers 01
Slide 39: Thank You
Thank You For further information, please get in touch with : Company Contact Company Contact Anoopkumar Pillai Dr Rahul Sawakhande Company Secretary CEO +91 84528 44024 +91 99304 96199 Investor Relations Contact Contact Name Soumya [email protected] +91 8619707750
Aakaar Medical Technologies — H1 FY27 Earnings Presentation on 6ix